• 精選課程
    外科手術
    內科用藥
    專業 3.0
    修課人數:180
    Post- 2024 EBCC Highlight

    Post- 2024 EBCC Highlight 即將於4/29(一)18:50-21:20線上直播,歡迎各位會員踴躍加入我的課程,聆聽歐洲最新乳癌治療趨勢!

     

     

  • 精選課程
    內科用藥
    專業 2.0
    修課人數:54
    Meet the Expert-與大師有約

    2024與大師有約系列複習課程! 當紅炸子雞 Prof. Paolo Tarantino 以及國內乳癌治療專家劉峻宇醫師共同擔任講者,由台大盧彥伸教授及台北榮總曾令民教授共同主持,ㄧ起深度討論如何治療HER2-low 的病人。

  • 精選課程
    內科用藥
    專業 2.0
    修課人數:239
    From clinical trials to real world practice of HR+HER2- mBC: Pre-menopausal patients線上直播

    Recent approved premenopausal patient reimbursement in Jan. 2024. Through this program we would like to review the current clinical reference and real world experience of treating  premenopausal patient to provide a clear picture based on reimbursement criteria, clinical reference and treatment experience.

  • 精選課程
    內科用藥
    專業 1.0
    修課人數:111
    PH FDC SC: The New Fixed-Dose Combination of Pertuzumab and Trastuzumab in One For Subcutaneous Use

    The recent approval of the fixed-dose combination of pertuzumab and trastuzumab (PH FDC SC) for subcutaneous injection provides a more convenient treatment option for HER2-positive breast cancer. This ready-to-use formulation combines two essential HER2-targeted antibodies in one single dose, delivering a proven efficacious regimen without compromising safety or outcomes compared to the standard intravenous preparations. By reducing administration time to just minutes, PH FDC SC maximizes patient comfort and flexibility. This innovative pharmaceutical solution epitomizes the next step forward in improving care delivery for the subset of breast cancer patients who can benefit from dual HER2 blockade. Ultimately, optimizing convenience through developments like PH FDC SC may help to reduce barriers to adherence.

  • 精選課程
    內科用藥
    專業 1.0
    修課人數:120
    HER2-Positive mBC Treatment Evolution: Leave No Option Behind

    The treatment of HER2-positive metastatic breast cancer (mBC) has advanced significantly in recent decades. Trastuzumab, introduced in 1998, improved survival when added to chemotherapy. Since then, other HER2-targeted agents like pertuzumab, T-DM1, and lapatinib have been approved, further extending progression-free and overall survival. These treatments have given most patients 2-4 years of disease control, but resistance still eventually develops. New strategies aim to prevent or overcome resistance by employing antibody-drug conjugates and combinations to hit multiple targets. The goal is to utilize all effective options in a sequential or combinatorial way until loss of benefit, thereby extending survival as long as possible.

  • 精選課程
    內科用藥
    專業 1.0
    修課人數:132
    Treatment Strategies for Early-Stage HER2-Positive Breast Cancer: A Review in Perspective

    HER2-positive breast cancer has a higher risk of recurrence even after standard chemotherapy and trastuzumab treatment. Neoadjuvant therapy prior to surgery provides benefits like potential downstaging and increased operability. Additionally, achieving pathological complete response (pCR) with neoadjuvant treatment correlates with improved survival. Optimal evaluation and selection of appropriate candidates for neoadjuvant therapy is thus critical. This review examines systemic neoadjuvant and adjuvant treatment strategies for HER2+ breast cancer to help guide clinical decision-making surrounding therapy selection. Key factors are assessing nodal involvement and recurrence risk to determine best approach, considering postsurgical outcomes with each strategy, and utilizing adjuvant T-DM1 if pCR is not achieved with neoadjuvant therapy in the case of residual disease.